My understanding is for GVHD, MSB is scheduled to meet the FDA this month for two purposes:
- Pathway to approval for Pediatric
- Agreement on the design protocols for P3 for adult
Following on from that a few possible scenarios:
- FDA accepts that the new potency assay data fulfils the CRL requirements. Then Mesoblast needs to resubmit the BLA. Then the FDA will determine the BLA classification and set a PDUFA date
- FDA does not accept that the assay data fulfils the CRL requirements. Then Mesoblast needs to be clear and agree on what the AA pathway is for Ryoncil Pediatric. This one will definitely require minutes from this FDA meeting. What is that pathway - commencement of the adult trial? Surrogate end-points? What are the processes/ procedures to be done to get the AA - that's a bit murky atm as the efficacy question has already been determined i.e. ODAC 9-1 vote
- FDA agrees/ disagrees on the design protocols for P3 for adult
Anyway, we'll find out all this soon - stay tuned!
GL MSB'ers - onwards and upwards
- Forums
- ASX - By Stock
- MSB
- Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-267
-
- There are more pages in this discussion • 283 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
95.0¢ |
Change
-0.045(4.52%) |
Mkt cap ! $1.093B |
Open | High | Low | Value | Volume |
$1.00 | $1.01 | 94.5¢ | $2.669M | 2.769M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2053 | 95.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
95.5¢ | 13191 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2053 | 0.950 |
5 | 69192 | 0.945 |
17 | 153239 | 0.940 |
10 | 194253 | 0.935 |
9 | 112676 | 0.930 |
Price($) | Vol. | No. |
---|---|---|
0.955 | 23191 | 3 |
0.960 | 60726 | 4 |
0.965 | 33726 | 1 |
0.970 | 53885 | 3 |
0.975 | 54219 | 6 |
Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
CC9
CHARIOT CORPORATION LTD
MD - Shanthar Pathmanathan, Geologist - David Trabert
MD - Shanthar Pathmanathan
Geologist - David Trabert
SPONSORED BY The Market Online